FLT3

A multi-targeted RTK inhibitor

A multi-kinase inhibitor

c-MET/TIE-2/VEGFR inhibitor

A potent JAK2 and PRK1 kinase inhibitor

Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC 50 values of 6 nM and 22 nM, respectively.

Quizartinib (AC220) is a highly potent second-generation Fms-like tyrosine kinase 3 (FLT3) inhibitor, with IC 50 values of 1.1nM and 4.2nM for FLT3-ITD and FLT3-WT, respectively.

inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

A potent and selective PDGFR family inhibitor

BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.

CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM).

FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 uM, detailed information refer to WO 2012158957 A2 and WO 2007013896.

Sitravatinib is a tyrosine kinase inhibitor (TKI) that targets the TYRO3, AXL, and MERTK (TAM) receptors, the vascular endothelial growth factor receptor (VEGFR) family, c-Kit, and c-MET.

Gilteritinib is a highly selective and oral FLT3 inhibitor with IC 50 values of 0.29nM and 0.73nM for FLT3 and AXL, respectively.

FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

MRX-2843 (UNC2371) (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively.

JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.

SKLB4771 (FLT3-IN-1) is a potent and selective Flt3 inhibitor with an IC50 value of 10 nM. SKLB4771 (FLT3-IN-1) downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue.

Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.

AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively.

BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11?nM.